The company has submitted its international patent application for recombinant human kallikrein-1 to the Patent Cooperation Treaty. It has also applied to China’s State Intellectual Property Office (SIPO) for a Chinese patent for the aqueous formulation for injection.
The company has submitted its application to SIPO for a Chinese patent for the multivalent tuberculosis.
Recombinant human kallikrein-1 is a product Sinobiomed is developing for the treatment of stroke and peripheral vascular disorders, and for the prevention of blood clots and thrombosis.